The specialized cardiac treatment centers segment is anticipated to register fastest CAGR during the forecast period

 Rise in geritric population, increase in prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. However, the hospitals segment held the largest share in 2019, accounting for more than three-fifths of the market. The integration of CRT pacemaker and cardiac resynchronization therapy defibrillator significantly reduced during the Covid-19 pandemic.

The U.S. Cardiac Resynchronization Therapy Market was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027.

The presence of favorable reimbursement policies, rise in investments, increase in technological advancements, and a growth in sedentary lifestyle among the U.S. population makes way for the growth of the cardiac resynchronization therapy market in the U.S. In addition, U.S. healthcare spending grew 4.6% in 2019 (as compared to 2018), reaching $3.8 trillion or $11,582 per person is expected to assist in the market growth over the forecast period.

Covid-19 scenario-

• The integration of CRT pacemaker and cardiac resynchronization therapy defibrillator significantly reduced during the Covid-19 pandemic.
• However, the demand is expected to slowly increase as the market gets back to its track.

Key Findings Of The Study-

• On the basis of type, the CRT defibrillator segment was the highest contributor to the U.S. cardiac resynchronization therapy market in 2019
• On the basis of application, the intraventricular dyssynchrony segment dominated the U.S. cardiac resynchronization therapy market in 2019, and is expected to continue this trend during the forecast period.
• On the basis of end user, the specialized cardiac treatment centers segment is anticipated to register fastest CAGR during the forecast period

The U.S. cardiac resynchronization therapy market report includes an in-depth analysis of the major market players such as Abbott Laboratories, Osypka Medical GmbH, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Medtronic plc, LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Lepu Medical Technology (Beijing) Co., Ltd.

Read More:

https://www.alliedmarketresearch.com/press-release/us-cardiac-resynchronization-therapy-market.html